Home / Market News / $DARE
fiscal.ai Corporate Catalyst Impact 65/100 ● neutral

Daré Bioscience Reports Third Quarter 2026 Financial Results

Nov 17, 2026, 2:21 PM UTC · Primary ticker $DARE

Daré Bioscience reported Q3 2026 financial results, noting initial revenue from Flora Sync LF5 and anticipated revenue from DARE to PLAY Sildenafil Cream, though not material for the full year. The company also highlighted recent payments for development programs, signaling progress towards a multi-product revenue stream in 2026-2027.

Daré Bioscience announced its Q3 2026 financial results, a routine disclosure for public companies. The key takeaway is the commencement of revenue generation from Flora Sync LF5 in July 2026 and the expectation of DARE to PLAY Sildenafil Cream revenue in Q4 2026, marking a transition from a purely development-stage company to one with commercial products. While these revenues are not expected to be material for the full year, they represent a significant step towards building a sustainable revenue profile, as emphasized by management. This news is positive for DARE as it validates their commercialization efforts and pipeline progress, potentially attracting investor interest in its future growth trajectory. The short-term impact might be moderate given the immaterial revenue, but it sets a positive long-term outlook for the company's revenue diversification and growth.

$DARE positive Initial product revenue and development payments
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.